Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead.

BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field turned to new targets that would extend efficacy beyond the subset of patients who respond to PD-1...